Stock.io

Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Amid New Phase 3 Trial

Raised Guidance Altering The Investment Case For Eli Lilly Stock?

Merck’s Pipeline Could Be Its Next Big Growth Driver. Its Latest Earnings Offer a Clue.

Forget Nvidia: Eli Lilly Will Become “the Most Valuable Company in the World,” Says Macro Investor

The U.S. Stocks Quietly Winning the Chinese Drug Boom